Suzanne Gazda, MD
Clinical Neurophysiology · Boerne, TXNPI 1740286764
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 381 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 41 manufacturers reported payments, led by Novartis at 24.5% of the total.
Across 381 payments — averaging $15.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- EMD Serono, Inc.$687
- Sanofi$524
- AbbVie$494
- TG Therapeutics, Inc.$382
- Bristol Myers Squibb$376
- plus $2K from 35 others
What the payments were for
- Food & beverage$5,988100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 115 | $1,465 |
| EMD Serono, Inc. | 62 | $687 |
| Sanofi | 23 | $524 |
| AbbVie(2 entities) | 27 | $494 |
| TG Therapeutics, Inc. | 19 | $382 |
| Bristol Myers Squibb | 24 | $376 |
| GE HealthCare | 11 | $247 |
| Johnson & Johnson | 11 | $187 |
| Octapharma USA, Inc. | 8 | $158 |
| Teva Pharmaceuticals USA, Inc. | 13 | $148 |
| Genentech USA, Inc. | 5 | $127 |
| Biogen | 7 | $117 |
| Acadia Pharmaceuticals Inc | 5 | $90 |
| Amgen | 5 | $86 |
| Abbott | 2 | $80 |
| UCB, Inc. | 3 | $74 |
| AstraZeneca | 3 | $70 |
| Mallinckrodt Hospital Products Inc. | 4 | $69 |
| Grifols USA, LLC | 3 | $61 |
| Sunovion Pharmaceuticals Inc. | 4 | $45 |
| Xeris Pharmaceuticals, Inc. | 2 | $44 |
| Kedrion Biopharma, Inc. | 2 | $39 |
| CSL Behring | 3 | $35 |
| Axsome Therapeutics, Inc. | 1 | $34 |
| ANI Pharmaceuticals, Inc. | 2 | $33 |
| Lilly USA, LLC | 2 | $33 |
| Argenx US, Inc. | 1 | $29 |
| Neurelis, Inc. | 1 | $28 |
| Impel Pharmaceuticals Inc. | 1 | $24 |
| Pfizer | 1 | $23 |
| Boston Scientific | 1 | $22 |
| Lundbeck LLC | 1 | $19 |
| Aprecia Pharmaceuticals, LLC | 1 | $18 |
| GRT US Holding, Inc. | 1 | $18 |
| Promius Pharma LLC | 1 | $16 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
| Shire North American Group Inc | 1 | $14 |
| Tanabe Pharma America, Inc. | 1 | $12 |
| Medtronic | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KESIMPTA$106
How this compares
$5,988 in reported general payments places this provider in the 65th percentile of 50 clinical neurophysiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 21 | $494,883 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 17 | $489,476 |
| Kesimpta PenOfatumumab | 28 | $242,181 |
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 13 | $165,982 |
| GlatopaGlatiramer Acetate | 36 | $143,157 |
| Glatiramer Acetate | 30 | $101,701 |
| CopaxoneGlatiramer Acetate | 14 | $81,125 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 15 | $73,190 |
| Teriflunomide | 33 | $48,947 |
| Dalfampridine ErDalfampridine | 29 | $26,450 |
| NuedextaDextromethorphan Hbr/Quinidine | 11 | $15,664 |
| Gabapentin | 75 | $1,580 |
| Baclofen | 37 | $988 |
| Memantine Hcl | 17 | $532 |
| Levetiracetam | 13 | $426 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerOctagam, Panzyga | $23 | $660,86434 claims |
| CSL BehringPrivigen | $35 | $489,47617 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $148 | $81,12514 claims |
| Grifols USA, LLCGamunex-C | $61 | $73,19015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 50 clinical neurophysiology providers in Texas.
Other clinical neurophysiology in Boerne
- Thy NguyenHouston$133K
- Nora Vanegas ArroyaveHouston$82K
- Samden LhatooHouston$66K
- Omotola HopeHouston$63K
- Kalarickal OommenLubbock$48K
- Hina DaveHouston$48K
- Monika UmmatHouston$36K
- Rony NinanPearland$16K
- Sudha TallavajhulaHouston$14K
- John HarneyRichardson$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.